

CTI BIOPHARMA CORP
Form 4
September 25, 2015

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
Plunkett Matthew

(Last) (First) (Middle)

3101 WESTERN AVENUE, SUITE 600

(Street)

SEATTLE, WA 98121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CTI BIOPHARMA CORP [ctic]

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2015

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

____ Director _____ 10% Owner
 Officer (give title below) _____ Other (specify below)

EVP, Corporate Development

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	09/24/2015		S ⁽¹⁾	3,600 D	\$ 1.52 797,353	D	
Common Stock	09/24/2015		S ⁽¹⁾	13,201 D	\$ 1.525 784,152	D	
Common Stock	09/24/2015		S ⁽¹⁾	200 D	\$ 1.5275 783,952	D	
Common Stock	09/24/2015		S ⁽¹⁾	6,899 D	\$ 1.53 777,053	D	
Common Stock	09/24/2015		S ⁽¹⁾	100 D	\$ 1.535 776,953	D	

Edgar Filing: CTI BIOPHARMA CORP - Form 4

Common Stock	09/24/2015	S ⁽¹⁾	289	D	\$ 1.54	776,664	D
Common Stock	09/24/2015	S ⁽¹⁾	600	D	\$ 1.545	776,064	D
Common Stock	09/24/2015	S ⁽¹⁾	800	D	\$ 1.55	775,264	D
Common Stock	09/24/2015	S ⁽¹⁾	800	D	\$ 1.56	774,464	D
Common Stock	09/24/2015	S ⁽¹⁾	1,700	D	\$ 1.57	772,764	D
Common Stock	09/24/2015	S ⁽¹⁾	1,000	D	\$ 1.575	771,764	D
Common Stock	09/24/2015	S ⁽¹⁾	5,330	D	\$ 1.58	766,434	D
Common Stock	09/24/2015	S ⁽¹⁾	7,000	D	\$ 1.585	759,434	D
Common Stock	09/24/2015	S ⁽¹⁾	16,400	D	\$ 1.59	743,034	D
Common Stock	09/24/2015	S ⁽¹⁾	1,500	D	\$ 1.595	741,534	D
Common Stock	09/24/2015	S ⁽¹⁾	14,400	D	\$ 1.6	727,134	D
Common Stock	09/24/2015	S ⁽¹⁾	1,390	D	\$ 1.605	725,744	D
Common Stock	09/24/2015	S ⁽¹⁾	660	D	\$ 1.61	725,084	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
--	--	--------------------------------------	--	--------------------------------	---	--	---	--	--

4, and 5)

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Code V (A) (D)				

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Plunkett Matthew 3101 WESTERN AVENUE, SUITE 600 SEATTLE, WA 98121			EVP, Corporate Development	

Signatures

By: Louis A. Bianco, Attorney-in-fact For: Matthew Plunkett

09/25/2015

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale was effected pursuant to a Rule 10b5-1 trading plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.